Manuel Carrondo,
Professor
Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and Philosophy Doctor
(1979) Environmental Engineering, Imperial College of Science and Technology, U. London;
Habilitation, Chemical Engineering (1991), Univ. Nova de Lisboa.
Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology,
Univ. Nova de Lisboa. Founder and earlier president (currently CEO) of IBET – Institute for
Experimental and Technological Biology (www.ibet.pt), founder and board member of the
Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE
(Council on Applied Science and Engineering) (1998-2001), chairman of the European Society
of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the
European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of
the External Advisory Group “Cell Factory” (Research Directorate General, European
Commission) (1998-2002), member of the Advisory Board of Max – Planck Institute for
Dynamics of Complex Technical Systems, Magdeburg, Amgen Bioprocessing Center, KGI,
Claremont, California, CEVEC Pharmaceuticals, Köln, PBS Biotech, California and CNIC -
Spanish National Center for Cardiovascular Research Carlos III, Spain.
Founder and CSO of GenIBET Biopharmaceuticals (2006-2008) (www.genibet.eu).
Meeting Chairman of the ESACT 14th Meeting “Animal Cell Technology: From Vaccines to
Genetic Medicine”, Vilamoura, May 1996 and of the “3rd Recombinant Protein Production
Meeting: A comparative view on host physiology"", Tavira-Algarve (Portugal), November
2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of
Technology - MIT (1988), Geselchaft für Biotechnologische Forschung (1989 and 1993).
Supervised twenty-eight Ph.D. students (thesis defended) and published over one hundred
ninety papers in refereed international journals; Associate-Editor of Journal of
Biotechnology, member of the editorial board of Biotechnology and Bioengineering, Current
Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress,
Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial
Biotechnology.
Key areas of research interest: Animal Cell Technology and its application for human and
animal health (http://tca.itqb.unl.pt). Therapeutic and diagnostic recombinant proteins,
including fusion proteins; virus like particles and pseudo viruses as vaccination agents and
viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells.
cGMP pilot plant scale-up and production development of biopharmaceuticals.
|
|
